Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and smaller biotechs.

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

The CTPA/siCSF1R system consists of a triblock polyamino acid (TPA) gene vector encapsulating siRNA, which is conjugated to the surface of photosynthetic cyanobacteria. It utilizes the inherent ...

Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile ...

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

The double-stranded RNA is processed by an RNase III family enzyme Dicer, resulting in the generation of an siRNA, a 21–23-nucleotide (nt) RNA duplex, composed of a 19-mer sequence with ...

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo Programs to focus on silencing hard-to-drug targets of high therapeutic ...

In SNALPs, the backbone-modified siRNA is encapsulated within a closed shell of a cationic-zwitterionic lipid bilayer, furnished with an outer PEG shield (Figure 2A). The lipid bilayer contains a ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...

ALY-101 is an intradermal injectable JAK1 siRNA-lipid conjugate for the treatment of Alopecia Areata <li /> Significant progress made in ...

Registration Link for Presentation and live Q&A to take place, Wednesday January 29, 2025 at 2:00 pm EST Marlborough, ...